Comparative Pharmacology
Head-to-head clinical analysis: BUSULFAN versus GLIADEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFAN versus GLIADEL.
BUSULFAN vs GLIADEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that crosslinks DNA, primarily at guanine N7 positions, leading to DNA strand breaks and inhibition of DNA replication and transcription. It is cell cycle phase-nonspecific.
GLIADEL (carmustine implant) is a biodegradable wafer that delivers carmustine, a nitrosourea alkylating agent, directly into the tumor resection cavity. Carmustine alkylates DNA and RNA, leading to cross-linking and inhibition of DNA replication, ultimately causing cell death. It is cell cycle phase nonspecific.
1-4 mg/day orally for remission induction in CML; 0.8-1 mg/kg every 6 hours orally for 4 days as part of myeloablative conditioning with cyclophosphamide.
Gliadel (carmustine) implant is administered intraoperatively as 8 wafers, each containing 7.7 mg carmustine, placed in the resection cavity after tumor debulking. Maximum dose is 61.6 mg (8 wafers).
None Documented
None Documented
Clinical Note
moderateBusulfan + Digoxin
"Busulfan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBusulfan + Digitoxin
"Busulfan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBusulfan + Deslanoside
"Busulfan may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBusulfan + Acetyldigitoxin
"Busulfan may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 2.5 to 4 hours (mean ~2.6 hours) after oral administration; prolonged to 3-5 hours with high-dose regimens. Half-life may increase with hepatic impairment.
Terminal elimination half-life is approximately 1.3 hours for the active dianhydrogalactitol metabolite. Clinical context: short half-life supports local interstitial delivery with minimal systemic accumulation.
Renal (10-50% unchanged), hepatic metabolism (primarily via glutathione S-transferases) with metabolites excreted in bile and urine. Fecal excretion minimal (<5%).
Primarily renal (60-70% as unchanged drug and metabolites) and biliary/fecal (15-20%). Approximately 10-15% is eliminated via exhaled air as CO2.
Category C
Category C
Alkylating Agent
Alkylating Agent